TheraRadar
← Back
Data updated: Jun 28, 2026

A G L WELDING SUPPLY CO INC

Pharma
Pharmaceuticals

A G L WELDING SUPPLY CO INC is a pharmaceutical company with 1 FDA-approved products.

2019
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Jul 11, 2026 — Relacorilant + nab-paclitaxel
0d
Jul 23, 2026 — Rivoceranib + camrelizumab
Jul 23, 2026 — Rivoceranib + camrelizumab

A G L WELDING SUPPLY CO INC's Key Drugs

A G L WELDING SUPPLY CO INC's core commercial portfolio centers on HELIUM, USP — its most strategically important drugs approved in the last 15 years.

A G L WELDING SUPPLY CO INC's Recent FDA Approvals

New NDA/BLA approvals for A G L WELDING SUPPLY CO INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

A G L WELDING SUPPLY CO INC's Therapeutic Areas

Disease areas where A G L WELDING SUPPLY CO INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

A G L WELDING SUPPLY CO INC Pipeline Snapshot

Active clinical trials for A G L WELDING SUPPLY CO INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • HELIUM, USP leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling